Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
49.23
-0.13 (-0.27%)
At close: Apr 17, 2025, 4:00 PM
49.31
+0.09 (0.17%)
After-hours: Apr 17, 2025, 4:31 PM EDT
BMY Employees
Bristol-Myers Squibb Company had 34,100 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
34,100
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
n/a
Market Cap
100.17B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 34,100 | 0 | - |
Dec 31, 2023 | 34,100 | -200 | -0.58% |
Dec 31, 2022 | 34,300 | 2,100 | 6.52% |
Dec 31, 2021 | 32,200 | 1,950 | 6.45% |
Dec 31, 2020 | 30,250 | 250 | 0.83% |
Dec 31, 2019 | 30,000 | 6,700 | 28.76% |
Dec 31, 2018 | 23,300 | -400 | -1.69% |
Dec 31, 2017 | 23,700 | -1,300 | -5.20% |
Dec 31, 2016 | 25,000 | 0 | - |
Dec 31, 2015 | 25,000 | 0 | - |
Dec 31, 2014 | 25,000 | -3,000 | -10.71% |
Dec 31, 2013 | 28,000 | 0 | - |
Dec 31, 2012 | 28,000 | 1,000 | 3.70% |
Dec 31, 2011 | 27,000 | 0 | - |
Dec 31, 2010 | 27,000 | -1,000 | -3.57% |
Dec 31, 2009 | 28,000 | -7,000 | -20.00% |
Dec 31, 2008 | 35,000 | -7,000 | -16.67% |
Dec 31, 2007 | 42,000 | -1,000 | -2.33% |
Dec 31, 2006 | 43,000 | 0 | - |
Dec 31, 2005 | 43,000 | 0 | - |
Dec 31, 2004 | 43,000 | -1,000 | -2.27% |
Dec 31, 2003 | 44,000 | 0 | - |
Dec 31, 2002 | 44,000 | -2,000 | -4.35% |
Dec 31, 2001 | 46,000 | 2,000 | 4.55% |
Dec 31, 2000 | 44,000 | -10,500 | -19.27% |
Dec 31, 1999 | 54,500 | -200 | -0.37% |
Dec 31, 1998 | 54,700 | 1,100 | 2.05% |
Dec 31, 1997 | 53,600 | 2,400 | 4.69% |
Dec 31, 1996 | 51,200 | 2,060 | 4.19% |
Dec 31, 1995 | 49,140 | 1,440 | 3.02% |
Dec 31, 1994 | 47,700 | -1,800 | -3.64% |
Dec 31, 1993 | 49,500 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
BMY News
- 1 day ago - U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications - Business Wire
- 2 days ago - 2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT - Business Wire
- 3 days ago - Why Is US Pharma Giant Bristol Myers Squibb Stock Trading Lower On Tuesday? - Benzinga
- 4 days ago - Bristol Myers' heart disease drug fails to meet main goals in late-stage study - Reuters
- 4 days ago - Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial - Business Wire
- 4 days ago - Trump says US pharma tariffs coming in not-too-distant future - Reuters
- 6 days ago - These Large-Cap Stocks With China And EU Exposure Got Crushed In The One Of The Most Volatile Trading Week (Apr 7-Apr 11): Are These In Your Portfolio? - Benzinga
- 7 days ago - U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma - Business Wire